Form 4: AngioDynamics Director Michael Tarnoff Acquires Shares as Part of Compensation Package

Director Michael Tarnoff acquired 20,541 shares of AngioDynamics common stock as part of his annual compensation.

Summary

• Michael E Tarnoff, a director of AngioDynamics Inc., reported a transaction involving the acquisition of company stock.
• On July 17, 2024, Tarnoff acquired 20,541 shares of AngioDynamics common stock.
• The acquisition was in the form of restricted stock units granted as annual compensation for his service as a director.
• The restricted stock units vested immediately upon grant.
• Following the transaction, Tarnoff beneficially owns 65,703 shares of AngioDynamics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a director's stock acquisition as part of their compensation. It doesn't inherently indicate positive or negative performance for the company.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future.

Industry Context

Director compensation in the form of stock and restricted stock units is a common practice in publicly traded companies to align the interests of management and shareholders.

Comparison to Industry Standards

• Director compensation packages vary widely across the medical device industry, depending on company size, performance, and governance practices.
• Companies like Medtronic, Boston Scientific, and Abbott also utilize stock-based compensation for their directors.
• The specific amount and vesting schedule of restricted stock units are typically determined by the compensation committee and approved by the board of directors.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with those of the shareholders.

Key Dates